| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/26/2002 | US6361760 Aerosol composition comprising tricyclic compound or pharmaceutically acceptable salt thereof, liquefied hydrofluoroalkane and medium-chain fatty acid triglyceride |
| 03/26/2002 | US6361758 Cosolvent formulations |
| 03/26/2002 | CA2230682C Sugar-free dragee-like products |
| 03/26/2002 | CA2216828C Controlled release insufflation carrier for medicaments |
| 03/26/2002 | CA2183486C Prostaglandin derivatives |
| 03/26/2002 | CA2097176C New pharmaceutical formulations containing a pharmacologically active ionizable substance as well as process for the preparation thereof |
| 03/26/2002 | CA2072513C Lozenge or chewable tablet |
| 03/26/2002 | CA2051260C Anti-oxidant system based on a basic amino acid associated with at least one tocopherol or one of its derivatives and at least one non-thiolated polypeptide, and compositions containing such an anti-oxidant system |
| 03/26/2002 | CA2034096C Controlled absorption naproxen formulation for once-daily administration |
| 03/22/2002 | CA2357526A1 Mannosidase structures |
| 03/21/2002 | WO2002022851A2 Novel tumor-associated marker |
| 03/21/2002 | WO2002022680A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 03/21/2002 | WO2002022677A2 Variants of allergenic proteins of the group 2 of dermatophagoides |
| 03/21/2002 | WO2002022657A2 Peptide antagonist of multiple chemokine receptors and uses thereof |
| 03/21/2002 | WO2002022554A1 Process and intermediates |
| 03/21/2002 | WO2002022174A1 A novel cationic lipopolymer as biocompatible gene delivery agent |
| 03/21/2002 | WO2002022172A2 Powdered/microfibrillated cellulose |
| 03/21/2002 | WO2002022171A2 Pharmaceutical composition having specific water activity |
| 03/21/2002 | WO2002022169A2 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS |
| 03/21/2002 | WO2002022164A1 Composition comprising immunogenic microparticles |
| 03/21/2002 | WO2002022163A1 Remedies for ischemic diseases |
| 03/21/2002 | WO2002022161A2 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | WO2002022160A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | WO2002022158A1 Selfemulsifiable formulation having enhanced bioabsorption and immunosuppression activities |
| 03/21/2002 | WO2002022154A2 Pharmaceutical compositions for sustained drug delivery |
| 03/21/2002 | WO2002022149A1 Use of il-6r/il-6 chimera in huntington's disease |
| 03/21/2002 | WO2002022136A1 Diphosphonate solutions |
| 03/21/2002 | WO2002022135A1 Creatine ester pronutrient compounds and formulations |
| 03/21/2002 | WO2002022134A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | WO2002022132A2 Novel topical oestroprogestational compositions with systemic effect |
| 03/21/2002 | WO2002022131A1 Eye drops |
| 03/21/2002 | WO2002022120A1 Pain reliever and method of use |
| 03/21/2002 | WO2002022109A2 Patch comprising diclofenac |
| 03/21/2002 | WO2002022108A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 03/21/2002 | WO2002022107A2 Pharmaceutical composition having modified carrier |
| 03/21/2002 | WO2002021996A2 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 03/21/2002 | WO2001098324A8 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
| 03/21/2002 | WO2001087982A3 Immunotoxin fusion proteins and means for expression thereof |
| 03/21/2002 | WO2001087039A3 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2 |
| 03/21/2002 | WO2001085845B1 Wound gels |
| 03/21/2002 | WO2001085800A3 Esterified polysaccharide products and η-lactone ring opened ketene dimer products containing the compositions, and process of making the same |
| 03/21/2002 | WO2001080831A3 Zero order release and temperature-controlled microcapsules and process for the preparation thereof |
| 03/21/2002 | WO2001080829A3 Taste masking coating composition |
| 03/21/2002 | WO2001078529A3 Compositions and methods for improving vascular health |
| 03/21/2002 | WO2001072958A3 Bladder cancer-specific peptides for diagnosis and therapy |
| 03/21/2002 | WO2001070694A8 Amorphous torasemide modification |
| 03/21/2002 | WO2001068092A3 Glycogen phosphorylase inhibitor |
| 03/21/2002 | WO2001056548A3 Liposomes composition produced by a dehydration-rehydration process |
| 03/21/2002 | WO2001054662A3 Compressed microparticles for dry injection |
| 03/21/2002 | WO2001051510A3 G-csf conjugates |
| 03/21/2002 | WO2001051026A3 Instant granules and process for their formulation |
| 03/21/2002 | WO2001045670A3 A stable immunogenic composition for frozen storage |
| 03/21/2002 | WO2001041812A3 Amphiphilic polymers and polypeptide conjugates comprising same |
| 03/21/2002 | WO2001037851A3 Use of ubiquinone q10 for the local treatment and prevention of post-surgical ophthalmologic pathologies |
| 03/21/2002 | WO2001035943A3 Dextrose and insulin fluid formulation for intravenous infusion |
| 03/21/2002 | WO2001035940A3 Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
| 03/21/2002 | WO2001030375A3 Use of gdnf for treating corneal defects |
| 03/21/2002 | WO2001003774A3 Pharmaceutical composition for the treatment of calcification |
| 03/21/2002 | US20020035264 Therapy for vision disorders |
| 03/21/2002 | US20020035248 Granules based on starch and lactose |
| 03/21/2002 | US20020035243 Drug complexes |
| 03/21/2002 | US20020035217 Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules |
| 03/21/2002 | US20020035161 O/W emulsions comprising micronized biologically active agents |
| 03/21/2002 | US20020035160 Topical applying; stability |
| 03/21/2002 | US20020035154 Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions |
| 03/21/2002 | US20020035152 Use of inhaled retinoids in the treatment of lung diseases |
| 03/21/2002 | US20020035151 Calcium formate for use as a dietary supplement |
| 03/21/2002 | US20020035135 Oral administering; storage stability |
| 03/21/2002 | US20020035107 Highly concentrated stable meloxicam solutions |
| 03/21/2002 | US20020035096 Formulations for treating or preventing mucositis |
| 03/21/2002 | US20020035093 Methods for the administration of amifostine and related compounds |
| 03/21/2002 | US20020035088 Formulated at a certain pH in order to minimize or eliminate compatibility problems between tobramycin and xanthan gum; eye, nose, ear topical solutions |
| 03/21/2002 | US20020035084 Protecting the agent (such as chemotherapeutic agent) within a lipid structure, causing lipase activity to be constituted in response to predetermined conditions, and exposing the lipid structure to release the agent |
| 03/21/2002 | US20020035082 Lipids where the glycerol backbone is replaced with a carbohydrate; conjugates; drug delivery |
| 03/21/2002 | US20020035076 Method of treating dermatoses using avermectin compound |
| 03/21/2002 | US20020035061 Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| 03/21/2002 | US20020034769 Novel glycolipid complexes and their uses |
| 03/21/2002 | US20020034554 Enhancing permeation of skin or mucosal tissue with topical hydroxide- releasing agent and lipophilic co-enhancer |
| 03/21/2002 | US20020034552 Micro- and nano- particles from oppositely charged, enzyme degradable polymers in which a drug is incorporated into the core and is conjugated by a Schiff-base crossling |
| 03/21/2002 | US20020034549 And plasticizer; for pharmaceutical dosage forms, food and confectionery tablets, seeds and granule cores |
| 03/21/2002 | US20020034548 Ascorbic acid, cationic polymers, cationic surfactants, humectants, polymers with humectant properties, inorganic driers; antiinflammatory agents, skin damage prevention, cosmetics |
| 03/21/2002 | US20020034546 Pharmaceutical composition containing a combination of a statin and aspirin and method |
| 03/21/2002 | US20020034542 Pharmaceutically acceptable steam extruded polymer, and medicament; rapid oral drug delivery or as vaginal or rectal suppositories or for oral delivery of veterinary drugs |
| 03/21/2002 | US20020034541 Oral solid pharmaceutical formulations with pH-dependent multiphasic release |
| 03/21/2002 | US20020034540 Solid non-effervescent compressed dosage form comprising an ibuprofen medicament and an alkali metal carbonate or bicarbonate carrier material and compressible filler component combined with disintegrating component |
| 03/21/2002 | US20020034539 Biphasic multicomponent pharamaceutical dosage forms containing substances able to modify the partitioning of drugs |
| 03/21/2002 | US20020034538 Liposomal benzoquinazolne thymidylate synthase inhibitor formulations |
| 03/21/2002 | US20020034537 For enhancing selective delivery of therapeutic, diagnostic and imaging agents to activated vascular sites |
| 03/21/2002 | US20020034536 Novel particulate formulations |
| 03/21/2002 | US20020034535 Rate controlling membranes for controlled drug delivery devices |
| 03/21/2002 | US20020034534 Receptor loading dosage form containing therapeutic agent and extended-release dosage form containing therapeutic agent administered concurrently |
| 03/21/2002 | US20020034532 Injectable depot gel composition and method of preparing the composition |
| 03/21/2002 | US20020034527 Antioxidants |
| 03/21/2002 | US20020034511 Radioactive labeling of biotin |
| 03/21/2002 | US20020034508 Binding antibody to epitopes |
| 03/21/2002 | US20020034506 Method for treatment of tumors using nucleic acid ligands to PDGF |
| 03/21/2002 | US20020034505 Genetic enginnering; kits |
| 03/21/2002 | US20020034498 Polymer-modified viruses |
| 03/21/2002 | US20020034474 Drug targeting system, method of its preparation and its use |
| 03/21/2002 | DE10138935A1 Synthetische Verbindungen vom Nicht-Mucintyp oder ihre mit einem Träger konjugierten Verbindungen Synthetic compounds from non-mucin or its conjugated with a carrier compounds |